Two of the major powers in the use of CRISPR-Cas9 in agriculture have reached a surprising arrangement that could accelerate the creation of genome-edited crops, giving companies a way to more easily license the intellectual property they need to make drought- or bug-resistant plants without worrying about being sued for patent infringement.

The agreement, announced on Wednesday and in effect immediately, is between the Broad Institute of MIT and Harvard, which holds dozens of key (but disputed) patents on the CRISPR genome-editing technology, and DuPont Pioneer, a major producer of genetically modified seeds. Pioneer licensed exclusive rights to agricultural uses of CRISPR from Caribou Biosciences, a spinoff of the University of California, Berkeley, and a second company, ERS Genomics. UC, Caribou, and ERS are allied in a heated patent fight against the Broad.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy